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47 year old male with metastatic melanoma  5 days of 
nausea, vomiting, polyuria, polydipsia
• No prior medical history of diabetes mellitus
• Melanoma of his lower back with inguinal lymph node 
metastases 
• Wide margin + sentinel lymph node 
excision
• 3 years later  CT Chest Abdomen Pelvis: metastatic 
pulmonary nodules, bladder wall nodule
• PET CT: lung nodules, mediastinal 
lymphadenopathy, gallbladder nodule, low 
back soft tissue mass, bladder lesion 
(extensive metastatic disease)
• Started on Nivolumab and Ipilimumab 
Vital Signs and Physical Exam: 
• Afebrile, pulse 114, BP 136/84, RR 22, SpO2 100% RA
• General: Pleasant adult male, well-
nourished, tachypneic and fatigued appearing.
• Abdomen: Soft, nontender, no palpable masses. 
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INTRODUCTION: Emergence of cancer immunotherapy has instigated a new era in field of oncology and revolutionized treatment of cancer. In 2011, Immune Checkpoint Inhibitors (ICI) gained 
approval for treatment of advanced solid and hematological malignancies and have had remarkable results. Since being released, new cases of irreversible endocrine adverse events are 
increasingly becoming reported and leave patients with a new life-long diagnosis after battling metastatic cancer. 
We present two cases of rare endocrinopathies after the use of ICIs. 
Case #2
Lab value Result











TSH, free T4 0.08, 1.47
Hospital Course
• Diagnosed with DKA   aggressive fluids, insulin drip. 
No underlying infection. 
• Pseudo-hyponatremia in the setting of hyperglycemia
• New prerenal AKI (dehydration)  hyperkalemia
• Adrenal insufficiency work up negative
• No stress dose steroids.
• Undetected C-peptide  new onset type I diabetes 
mellitus in the setting of nivolumab and ipilimumab
use. 
• Started on an insulin regimen outpatient
81 year-old female with metastatic bladder cancer  2 weeks 
of fatigue, positional dizziness, dyspnea
• Denied fever, chills, dysuria, abdominal pain
• Admitted 2 weeks prior with acute hyperkalemia from 
dehydration, poor appetite. 
• Bladder cancer 5 years ago, underwent TURB x3
• 4 years later  mediastinal metastases
• Started on Cisplatin and Gemcitabine
• Due to progression of her cancer  switched to 
Pembrolizumab (Keytruda)
Vital Signs and Physical Exam: 
• Afebrile, pulse 90, BP 81/59, RR 16, SpO2 97% on RA
• General: Pleasant, thin female, mildly dyspneic in the room. 
Dry mucous membranes.
• Cardiac: Low JVP
• Skin: No hyperpigmentation noted
Lab Results
Lab value Result













• Started on empiric antibiotics for urosepsis
• Persistent hypotension  further work up for  adrenal 
insufficiency
• Undetected morning cortisol + elevated ACTH 
 Primary Adrenal Insufficiency due to 
Keytruda
• 21-hydorxylase enzymes not checked
• Started on hydrocortisone
• On outpatient follow up  persistent dizziness, 
hyperkalemia, fludrocortisone added. 
Discussion
• 6 Immune Checkpoint Inhibitors (ICIs) approved: 
• CTLA-4 (cytotoxic T-lymphocyte-associated 
protein 4) inhibitor Ipilimumab
• PD-1 (programmed cell death protein 1) 
inhibitors nivolumab, pembrolizumab
• PD-L1 (programmed cell death ligand 1) 
inhibitors atezolizumab, avelumab, 
durvalumab
• T-cell surface receptors  immunological tolerance to 
self-antigens, prevent autoimmune disorders
• Endocrine dysfunction – most common adverse effect 
• Hypothyroidism, hyperthyroidism, 
hypophysitis, primary adrenal insufficiency, 
insulin-deficient diabetes
• Higher with combination therapy
• Thyroid dysfunction most common 
• Life-threatening thyroid storm: anti-PD1 
agents
• Destructive thyroiditis by cytotoxic cells 
against thyroid gland (thyroid gland expresses 
both PD-L1, PD-L2 molecules)
• Hypophysitis most common with ipilimumab (CTLA-4 
protein expressed in pituitary glands)
• Primary adrenal insufficiency – very rare (0.7%)
• Insulin-dependent diabetes: with anti-PD1 therapy and 
Ipilimumab 
• Current guidelines recommend baseline screening with 
TFTs, morning cortisol and ACTH and screening monthly 
thereafter. 
• CTA Chest: No consolidation, pulmonary embolus.  
Enlarged mediastinal lymph nodes. 
• CT Abdomen-Pelvis W Contrast: Unremarkable
• Urinary Analysis (UA): 2+ Leukocyte esterase, 25-50 
WBC, 1+ bacteria
